Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome

BACKGROUND & AIMS: Options for the prevention of short-bowel syndrome–associated liver disease (SBS-ALDs) are limited and often ineffective. The farnesoid X receptor (FXR) is a newly emerging pharmaceutical target and FXR agonists have been shown to ameliorate cholestasis and metabolic disorders...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira-Fantini, Prue M., Lapthorne, Susan, Gahan, Cormac G.M., Joyce, Susan A., Charles, Jenny, Fuller, Peter J., Bines, Julie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439235/
https://www.ncbi.nlm.nih.gov/pubmed/28560290
http://dx.doi.org/10.1016/j.jcmgh.2017.02.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439235/
https://www.ncbi.nlm.nih.gov/pubmed/28560290
http://dx.doi.org/10.1016/j.jcmgh.2017.02.008

Ejemplares similares